“We don’t want fear. There’s no needle, there’s no pain with this product,” he said. “It’s basically like spraying saline ...

expanding options beyond needle-based treatments like the EpiPen. The nasal spray, called Neffy, from drugmaker ARS ...

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to ...

The third quarter of 2024 has been a significant period for ARS Pharmaceuticals, marked by the U.S. commercial launch of neffy, the first needle-free epinephrine treatment for Type I allergic ...

ARS Pharmaceuticals Inc (NASDAQ:SPRY) received approval for NEPHI 2 mg in both the United States and Europe, marking it as the first needle-free epinephrine product for allergic reactions.

The licensing deal will see American pharma company ARS retain the rights for the needle-free treatment for anaphylaxis in the US, Australia, New Zealand, Japan and China, while Danish allergy ...

Stock analysts at Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of ARS Pharmaceuticals in a report issued ...